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The effect of rifampin on the replication of MVL51, a bullet-shaped mycoplas-
mavirus with single-stranded circular DNA of molecular weight 2 x 106, has
been examined in a rifampin-resistant host cell. Rifampin does not block the
early steps in MVL51 infection but does decrease the total amount of parental
viral DNA taken up. The single-stranded parental viral DNA that enters the
cell is found in membrane-associated, double-stranded DNA replicative forms I
and II. Rifampin had no significant effect on the synthesis ofprogeny viral DNA
RFI and RFII early in infection and SSI (single-stranded progeny viral chromo-
somes) later in infection. The rifampin block in virus synthesis was found to be
in the step converting SSI into assembled virions. Rifampin was shown to affect
the synthesis of virus-specific RNA, which suggests that viral transcription is
necessary for virion assembly.
MVL51 is a group Li mycoplasmavirus,
which are bullet-shaped particles (about 15 by
80 nm) having helical capsid symmetry and
containing single-stranded circular DNA ofmo-
lecular weight 2 x 106 (8, 10). Viral infection is
nonlytic, and infected cells continue to grow
and extrude progeny viruses (9). Replication of
MVL51 has been shown to involve three viral
DNA intermediates: RFI, covalently closed cir-
cular double-stranded DNA; RFII, a nicked
form of RFI; and SSI, a circular, single-
stranded progeny viral DNA. RFI and RFII are
precursors for the synthesis of SSI (6).
The antibiotic rifampin specifically inhibits
initiation of transcription by RNA polymerase.
In this paper, we report the effect ofrifampin on
the synthesis of MVL51 in-a rifampin-resistant
host. These data show that virus production is
inhibited at concentrations of the antibiotic
that have no effect on cell growth. The anti-
biotic does not inhibit synthesis ofvirus-specific
DNAs but inhibits synthesis of some virus-spe-
cific RNA required for maturation and/or
release.
MATERIALS AND METHODS
Cells, viruses, medium, and buffer. Achole-
plasma laidlawii JAl was used for virus growth and
as the indicator host in these studies. The virus used
was MVL51, a group Li mycoplasmavirus described
by Liss and Maniloff (9). Cells and viruses were
cultivated in tryptose broth or on tryptose agar
plates as described previously (9).
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The Tris-EDTA-NaCl buffer (pH 8.0) used was
0.01 M Tris, 0.001 M EDTA, 0.1 M NaCl, and Tris-
EDTA-NaCl-NaCN buffer was the same buffer con-
taining 10mM NaCN. The high-salt buffer was Tris-
EDTA-NaCl containing 1 M NaCl.
Antibiotics. Rifampin and chloramphenicol were
obtained from Sigma Chemical Co. (St. Louis, Mo.).
Rifampin solutions were made up in Tris-EDTA-
NaCl buffer 1 day before use and stored at 4 C in the
dark.
Preparation of labeled virus. Radioactively la-
beled MVL51 and viral DNA were prepared as de-
scribed previously (6).
Analysis of whole cells. For examination of the
effects of antibiotics on the incorporation of radioiso-
topically labeled compounds in whole cells, log-
phase cultures of JAl cells were treated with either
rifampin or chloramphenicol. After different times
5-ml aliquots were removed, centrifuged, and sus-
pended in 5 ml of Eagle basal medium containing
the antibiotic and either 10 ,uCi of [3H]uridine or 20
juCi of L-[3H]amino acid mixture per ml (New Eng-
land Nuclear Corp., Boston, Mass.). The rate of
incorporation of labeled precursors into cellular
macromolecules has been found to be better in this
labeling medium than in the tryptose growth me-
dium (13). After 3 min of labeling, cells were precipi-
tated by adding 5 ml of ice-cold 10% trichloroacetic
acid. The precipitate was collected on membrane
filters (0.45-Mm pore size; Millipore Corp.), washed,
and counted for radioactivity.
Preparation of virus-infected cell lysates. A log-
phase culture ofA. laidlawii JAl was infected with
either 32P-labeled or unlabeled virus. To remove
unadsorbed virus, after 5 min cells were spun down
at 12,000 x g for 10 min, and the pellet was washed
with Tris-EDTA-NaCl and suspended in prewarmed
tryptose broth. At different times after infection,
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antibiotic was added to the infected culture, and,
after a specified interval, the cells were labeled for
varying periods with [3H]deoxythymidine. Labeling
was terminated by adding an equal volume of ice-
cold Tris-EDTA-NaCl-NaCN buffer and centrifug-
ing at 12,000 x g for 10 min at 5 C. The cell pellet
was washed and lysed by 0.4% (final concentration)
Sarkosyl NL97 as described previously (6). For iso-
lating membrane-associated viral DNA, the infected
cell suspension was gently lysed by freezing in liq-
uid nitrogen and thawing (J. Das and J. Maniloff,
Proc. Natl. Acad. Sci. U.S.A., in press).
Sucrose gradient centrifugation. One to two mil-
liliters of an infected cell lysate was layered on top of
38 ml of a 5 to 20% (wt/vol) sucrose gradient in Tris-
EDTA-1 M NaCl buffer. For isolating membrane-
associated viral DNA, a 5 to 20% high-salt sucrose
gradient was formed over a CsCl shelf. The gra-
dients were centrifuged and fractionated as de-
scribed previously (Das and Maniloff, in press).
Radioactive assay. Gradient fractions were pre-
cipitated by adding an equal volume of ice-cold 10%
trichloroacetic acid, using bovine serum albumin as
carrier. The precipitated samples were filtered,
washed, dried, and assayed for radioactivity as pre-
viously described (6).
RNA-DNA hybridization. Pulse-labeled RNA was
isolated from uninfected, infected, and infected rif-
ampicin-treated JAl cells by the method described
by Mitra (11). For the infected cell experiment, a
log-phase JAl culture was infected with MVL51 at a
multiplicity of infection of about 10. Thirty minutes
after infection, rifampin (100 /.g/ml) was added to
part of the infected culture. Twenty-five minutes
later, cells were labeled for 5 min with 40 ACi of[3H]uridine per ml. At the end of the labeling pe-
riod, cells were rapidly chilled, centrifuged, washed
with saline phosphate, and, finally, suspended in
0.05 M sodium acetate (pH 5.0). Sodium dodecyl
sulfate (0.5% final concentration) and polyvinyl sul-
fate (10 ug/ml final concentration) were then added.
After 5 min at 4 C, the cell suspensions were ex-
tracted twice with phenol saturated with 0.15 M
NaCl, 0.015 M sodium citrate (SSC), pH 7.0. The
phenol phase was reextracted with 0.05 M sodium
acetate (pH 5.0). The aqueous layers were pooled
and precipitated with 3 volumes of ethanol at - 20 C
for 24 h. The nucleic acid precipitate was collected
by centrifugation at 4,000 x g for 10 min and resus-
pended in SSC.
MVL51 replicative form (RF) DNA was isolated
from sucrose gradients as previously described (6),
dialyzed against SSC, and denatured by heating at
100 C for 10 min and chilling rapidly.
The reaction mixture for hybridization contained
0.5 M KCl, 0.01 M Tris-hydrochloride (pH 7.5),
pulse-labeled RNA, and denatured RF DNA. The
reaction mixture was incubated for 30 min at 67 C
and then cooled to room temperature. After 20 min
at room temperature, pancreatic RNase (10 /ig/ml)
was added, and after 1 min the mixture was diluted
with 5 volumes of KCl-Tris-hydrochloride buffer,
filtered through a 0.45-,um membrane filter (Milli-
pore Corp.), washed twice with the same buffer,
dried, and counted.
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Assay of RNA polymerase. Uninfected and in-
fected cells, after 60 min of infection in tryptose
broth, were centrifuged at 7,500 x g for 10 min and
suspended in 1 ml of buffer A (0.05 M Tris, 0.05 M
EDTA, 0.01 M MgCl2, 0.01 M f8-mercaptoethanol,
pH 8.0) (3). The cells were disrupted by sonication
and centrifuged at 12,000 x g for 10 min. The super-
natant was decanted, 0.2 volume of 1% protamine
sulfate was added, and the mixture was centrifuged
at 12,000 x g for 10 min. The precipitate was resus-
pended in 1 ml of buffer A. For the RNA polymerase
assay, 100 ,ul of the resuspended precipitate was
used without further purification. The enzyme was
assayed by the method of Berg et al. (2), using
[3H]uridine as labeled nucleotide and highly poly-
merized calf thymus DNA (150 ,ug/ml) as template.
Potassium phosphate (20 mM) was added to the
reaction mixture to inhibit polynucleotide phospho-
rylase. The enzyme fractions were preincubated for
5 min at room temperature before adding the DNA.
The enzyme activity was measured after 10 min of
incubation at room temperature and corrected for
endogenous DNA by measuring incorporation of
[3H]uridine in the absence of added DNA.
RESULTS
Growth of infected and uninfected cells in
the presence of rifampin. During studies of the
effect of rifampin on the replication of myco-
plasmavirus MVL51 (to be described below), it
was observed that the A. laidlawii JAl indica-
tor host, which was used in these and all pre-
vious virus studies in this laboratory, was ri-
fampin resistant. The effect of rifampin on the
growth of uninfected and MVL51-infected A.
laidlawii JAl cells is shown in Fig. 1. Growth
of uninfected cells (Fig. la) was not affected by
low antibiotic concentrations (up to 50 ug/ml).
At 100 ,tg/ml, cell growth continued for 3 h;
similar results were found at 200 ,ug/ml.
Growth of MVL51-infected cells in the presence
of 100 ,ug of rifampin per ml (Fig. lb) was
similar to that of infected untreated cells.
Effect of rifampin on cellular RNA and pro-
tein synthesis. Incorporation of [3H]uridine in
cells treated with 100 Ag ofrifampin per ml was
not affected for 2 to 3 h after the addition of the
drug, after which the incorporation was re-
duced (Fig. 2b). For comparison, in cells treated
with 100 ,g of chloramphenicol per ml, uridine
incorporation continued at the untreated con-
trol cell rate for 1 h and then stopped.
Protein synthesis (Fig. 2a), as measured by
incorporation of labeled amino acids, was
barely affected by 100 ,g of rifampicin per ml,
whereas it was completely inhibited by 100 ,tg
of chloramphenicol per ml.
Effect of rifampin on cellular RNA polym-
erase. In vitro assays of the RNA polymerase
activity in extracts from infected and unin-
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FIG. 1. (a) Growth ofJAl cells in the presence ofrifampin. The drug concentrations were: (0) control; (A)
20 pug/ml; (A) 50 pg/ml; and (O) 100 puglml. (b) Growth ofMVL51 -infected JAl cells in thepresence ofl 00 pg
of rifampin per ml. Symbols: (A) uninfected and (0) infected cells without rifampin; (O) infected cells plus
100 pg of rifampicin per ml.
TIME (hbs)
FIG. 2. Incorporation of (a) [3HJamino acids and
(b) [3H]uridine into trichloroacetic acid-insoluble
material after addition of (A) 100 pg of rifampicin
per ml, (0) 100 pg ofchloramphenicol per ml, or (0)
control.
fected A. laidlawii JAl cells were performed in
the presence of different concentrations of ri-
fampin to examine the rifampin sensitivity of
the RNA polymerase of these cells. The results
(Fig. 3) show that the enzyme from both
MVL51-infected and uninfected cells was resist-
ant to rifampin. Even 100 ,ug of the antibiotic
per ml only inhibited about 50% of the in vitro
RNA polymerase activity.
Viral growth in the presence of rifampin.
The effect of rifampin on MVL51 viral growth
was examined. At various times after the start
of infection, a sample of an infected cell culture
was removed and treated with 100 ug of the
antibiotic per ml. One hour after the addition of
the drug, PFU were assayed. The untreated
culture showed the characteristic growth curve
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FIG. 3. RNA polymerase activity in extracts from
infected and uninfected JAl cells in the presence of
rifampin. The activity is expressed as percentage of
activity in the absence of the drug. Symbols: (0)
uninfected cells; (0) cells infected with MVL51.
for this nonlytic virus (Fig. 4). Rifampin treat-
ment inhibited the growth of the virus, but the
extent of inhibition depended upon when dur-
ing infection the antibiotic was added (Fig. 4a).
The amount of inhibition increased with in-
creasing infection times. For comparison, a par-
allel experiment was performed with 100 gg of
chloramphenicol per ml. Chloramphenicol com-
pletely inhibited virus production independent
of the time during infection of addition of the
drug (Fig. 4b).
The effect of 2-h treatments of different ri-
fampin concentrations is shown in Fig. 5. Ri-
fampin concentrations, which had been found
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to have little or no effect on growth of unin-
. < fected (Fig. la) and infected cells (Fig. lb), were
found to inhibit viral production by 90% or
,0.10 / . / more.
. -"' 0t ---Reversibility of rifampin effect. To examine
::/- whether the effect of rifampin on virus growth
could be reversed, 100 gtg of rifampin per ml
was added to infected cells 100 min after infec-
--ihc-- ~ ~tion and the culture was incubated for 1 h. At
the end of this period the cells were removed
from the antibiotic-containing medium, and the
: 0 . infected cell pellet was washed and resus-
pended in prewarmed tryptose broth. PFU were
assayed before and Ifter the removal of the
________.___.___._____ antibiotic. PFU. production was almost com-
- TIME5hr pletely inhibited by 1 h ofdrug treatment at 100
FIG. 4. Effect ofrifampin and chloramphenicol on min after infection. After the removal of the
virus growth. A log-phase culture of JAl cells was antibiotic, there was a lag of about 30 min, and
infected with MVL51 at a multiplicity of infection of then virus production began at about the same
3. After 5 min, cells were centrifuged to remove un- rate as untreated cells (Fig. 6).
adsorbed viruses and infected cells were resuspended Effect of rifampin on virus-specific RNA
in tryptose broth. At different times after infection synthesis. The data presented above show that
aliquots were removed and virus assays were per- rifampin inhibits production of virus, although
formed, before and after 1-h treatments with either the RNA polymerases from infected and unin-
100 Mg of (a) rifampicin or (b) chloramphenicol per
ml. Symbols: (0) control; (0) virus titer after 1-h
drug treatment.
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FIG. 5. Effect of rifampin concentration on virus
yield. The protocol was as in the legend to Fig. 4,
except that 5 min after infection the cells were trans-
ferred to medium containing different concentrations
ofrifampin. PFU were assayed 2 h after the transfer.
The broken line indicates virus titer at the time of
rifampin addition.
TIME (hrs)
FIG. 6. Reversibility of the effect of rifampin on
virus synthesis. Cells were infected as in the legend to
Fig. 4. At 100 min after infection (arrow), an aliquot
of infected cells was treated with 100 jig of rifampin
per ml for 1 h. The cells were then centrifuged,
washed, and resuspended in fresh tryptose broth.
Symbols: (0) control; (0) treated infected cells after
rifampin removal.
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fected cells are resistant to the drug. This effect
could be due to rifampin only inhibiting the
synthesis of virus-specific RNA. To test this
possibility, pulse-labeled RNA was isolated
from uninfected, MVL51-infected, and infected
and rifampin-treated JAl cells and hybridized
with MVL51 RF DNA. The results are shown
in Table 1. The amount ofRNA hybridized was
maximum when RNA from infected cells was
used. This amount was reduced 2.5-fold when
infected cells were treated with 100 ,ug of rifam-
picin per ml for 30 min. Hence, rifampin in-
hibits the synthesis of virus-specific RNA. The
activity bound in the filters when RNA from
uninfected cells was used may be due to cellu-
lar DNA contamination in the RF preparation.
Effect of rifampin on parental RF forma-
tion. To examine the effect of rifampin on the
early steps in viral replication, JAl cells were
either pretreated with the antibiotic before in-
fection or the antibiotic was added along with
the virus. Infected cells were then analyzed for
the amount of parental viral DNA in subcellu-
lar fast (membrane-associated)- and free-sedi-
menting fractions (Table 2). The total amount
of parental viral DNA recovered in the cells
(i.e., in the fast- and free-sedimenting .frac-
tions) was reduced when rifampin was added at
the start of infection and decreased further by
30-min pretreatment of the cells by rifampin
before infection. Longer rifampin pretreatment
(up to 60 min) caused no further decrease in
recovery of intracellular parental viral DNA
(data not shown).
The distribution of parental label shows a
marked decrease in the amount of free-sedi-
menting parental viral DNA relative to fast-
sedimenting DNA in rifampin-treated infected
cells compared to untreated infected cells.
Hence, rifampin treatment decreases the
amount of uptake of parental viral DNA and
shifts the intracellular distribution of the viral
TABLE 1. Hybridization of 3H-labeled RNA with
MVL51 RF DNA
3H bound to
membrane
Ipt Sp act filter con-Source ofRNA (counts/min) (counts/mm taming RF(contsmm)per A260) DNA
(counts/
min)
Uninfected cells 1.40 x 104 8.2 x 103 90
Infected cells 1.37 x 104 7.7 x 1003 446
Infected cells + 1.43 x 104 8.9 x 103 173
100 gg of ri-
fampin per ml
a A2, Absorbancy units at 260 nm.
DNA, which is incorporated so that it is almost
totally recovered in a membrane-associated
form. The result of these two effects is that only
60% of the parental viral DNA that can be
recovered as fast-sedimenting material in un-
treated cells is found as fast-sedimenting mate-
rial in rifampin-treated cells. The free-sedi-
menting parental viral DNA in rifampin-
treated cells is reduced to 7% of that found in
untreated cells.
To examine the conversion of parental DNA
to RF forms, cells were either untreated or
treated for 30 min with 100 ug of antibiotic per
ml before infection with labeled viruses. Ten
minutes after infection, the cells were washed,
lysed by Sarkosyl NL97, and sedimented
through a 5 to 20% sucrose gradient containing
1 M NaCl, as described in Materials and Meth-
ods. The single-stranded DNA of MLV51 was
found in double-stranded replicative forms RFI
and RFII (Fig. 7a). This conversion was not
affected by pretreating cells for 30 min with 100
,ug of.rifampin (Fig. 7b) or 100 Mug of chloram-
phenicol (Fig. 7c) per ml, indicating that preex-
isting cell enzyme(s) and cell-specific transcrip-
tion can perform the initial steps of MVL51
DNA replication.
Effect of rifampin on synthesis of progeny
viral DNA. To examine the effect ofrifampin on
RF replication and single-stranded progeny
viral DNA synthesis, infected cells were
treated for 30 min with 100 Mg of rifampin per
ml at 0 and 90 min after infection. During the
last 10 min of antibiotic treatment at each time,
[3H]deoxythymidine was added to the culture to
label the nascent DNA. A parallel infected cul-
ture was not rifampin treated.
It has been shown (6) that, during the first 30
to 40 min of MVL51 infection, RF replication
predominates, after which there is a shift to the
synthesis of SSI. The synthesis ofprogeny viral
RF molecules in untreated cells and cells
treated with rifampin during the first 30 min of
infection was similar (Fig. 8a). Infected cells
treated with rifampin during 90 to 120 min
after infection made progeny SSI, but no nas-
cent viral DNA could be found in the gradient
fraction corresponding to completed virus parti-
cles (Fig. 8b). Lysates of untreated infected
cells late in infection show this virus peak,
since the lysis procedure used does not disrupt
virus particles (6). The peak must represent
viruses in the process of being extruded.
The amount of nascent virus-specific DNA
found in the lysates of rifampin-treated cells
was greater than in untreated cells (Fig. 8b).
This difference could account for the amount of
cold trichloroacetic acid-precipitable radioactiv-
ity in the cell-free supernatant of the untreated
VOL. 18, 1976
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TABLE 2. Effect of rifampin pretreatment on penetration and membrane association of viral DNA
Total amt ofparental viral DNA Distribution of parental labelin cells
__ _ _ _ __ _ _ _ __ _ of_parental _label
Treatment % Relative Fast-sedimenting complex Free-sedimenting material
Counts/min to untreated ttl
cells Counts/min
c
of total Counts/min % of total
Untreated 1,167 100 836 72 331 28
Rifampin (100 831 71 735 88 96 12
,ug/ml) added
at start of in-
fection
Infection started 522 45 500 96 22 4
after 30-min
rifampin (100
,tg/ml) pre-
treatment
Infection started 498 43 478 96 20 4
after 30-min
rifampin (200
,ug/ml) pre-
treatment
a Infection was with 32P-labeled MVL51 at a multiplicity of infection of 10. Fast- and free-sedimenting
material were analyzed, as described in Materials and Methods, 10 min after the start of infection.
infected cells. Hence, the difference in amounts
of progeny viral DNA between untreated and
treated cells in Fig. 8b is due to the release of
nascent DNA in progeny viruses from the un-
treated cells.
To examine whether the single-stranded
progeny viral DNA accumulated during rifam-
pin treatment could be assembled into progeny
particles upon removal of the drug, part of the
rifampin-treated sample (shown in Fig. 8b) was
centrifuged and the cells were resuspended in
prewarmed tryptose broth to remove the rifam-
pin. Forty minutes after resuspension, a cell
lysate was prepared and sedimented through a
high-salt sucrose gradient. It was found (Fig.
8c) that some of the virus-specific DNA synthe-
sized during rifampin treatment could now be
recovered at the virus particle position. The
total amount of radioactivity in intracellular
viral DNA decreased after rifampin removal
(cf. Fig. 8b and c) but was recovered as cold
trichloroacetic acid-insoluble material in the
cell-free supernatant, indicating the release of
progeny virus.
DISCUSSION
The indicator host used in these studies, A.
laidlawii JAl, is rifampin resistant, as shown
by the inability of rifampin to inhibit cell
growth (Fig. la) and RNA and protein synthe-
sis (Fig. 2). In considerations of whether the
rifampin resistance could be due to a permea-
bility barrier, it should be noted that A. laid-
lawii, like other mycoplasmas, does not have a
cell well and is bounded by a single 7-nm lipo-
protein cell membrane (4). The observation
that virus (but not cell) growth is inhibited by
rifampin treatment (Fig. lb and 4) means that
the antibiotic must be getting into the cell. The
resistance of cellular RNA polymerase activity
to rifampin, in an in vitro assay (Fig. 3), con-
firms the whole-cell data.
The results presented here show that rifam-
pin does not block the early steps in MVL51
infection but does decrease the total amount of
parental viral DNA taken up by the indicator
cells. The single-stranded parental viral DNA
that enters the cell is found in membrane-asso-
ciated, double-stranded DNA RFI and RFII
(Fig. 7; Table 2). Rifampin had no significant
effect on the synthesis of progeny viral DNAs;
early in infection this synthesis was mainly in
RF molecules and later in infection in SSI DNA
(Fig. 8a and b). The rifampin block in virus
synthesis was seen to be in the step converting
SSI (progeny viral chromosomes) into assem-
bled virions. Removal of rifampin allowed these
progeny SSI molecules to be packaged and re-
leased (Fig. 8c).
Parenthetically, it was noted that late in in-
fection rifampin treatment led to a larger accu-
mulation of RFII molecules, relative to RFI and
SSI, than would be expected at this infection
time (Fig. 8b). This suggests the possible exist-
ence of a reusable protein (similar to the gene 5
product of bacteriophage M13; 12) mediating
the conversion of RFII to SSI. The rifampin
block in virus assembly, causing the accumula-
J. VIROL.
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FIG. 7. Velocity sedimentation of infected cell ly-
sates. JAl cells were grown to 5 x 108 cellslml and
treated with either 100 pg of rifampin or 100 pg of
chloramphenicol per ml for 30 min. 32P-labeled
MVL51 was then added to a multiplicity of infection
of2O. After 10 min at 37 C, unadsorbed viruses were
removed by washing and the infected cell pellet was
resuspended in ice-cold Tris-EDTA-NaCl buffer.
Cells were lysed by 0.4% SarkosylNL97, layered on 5
to 20% sucrose gradients containing I M NaCl, and
centrifuged at 24,000 rpm for 16 h in an SW27 rotor.
The direction ofsedimentation was from left to right.
(a) Untreated; (b) rifampin treated; (c) chloram-
phenicol treated. The SSI position was determined
from a parallel gradient ofpurified viral DNA, and
the RFI and RFII positions were calculated from
their sedimentation rates relative to SSI, as given in
Das and Maniloff (6).
tion of SSI molecules, would exhaust the pool of
such a protein, resulting in the buildup of RFII.
Experiments to explicitly demonstrate and iso-
late this protein are in progress.
Rifampin was shown to affect the synthesis of
some virus-specific RNA (Table 1). This obser-
vation, together with the data that the rifam-
pin block in virus synthesis is in the conversion
of progeny viral chromosomes into assembled
particles, suggests that virus-specific transcrip-
tion is necessary for this assembly step. The
rifampin sensitivity of this viral transcription
in rifampin-resistant cells could be due to sev-
eral possibilities. First, the MVL51 mycoplas-
mavirus, like coliphage T7 (5), could code for its
own RNA polymerase. In view of the limited
coding capacity of MVL51 and the large size of
such a polymerase, this possibility appears un-
likely. Second, a viral gene product or a cellular
virus-specific factor, similar to those reportedfor coliphages T4 (14) and X (7), might modify
RFX RFI SSI MVL 5S1.2. a. 4 4 f 4
0.8.
0.4.
o b.
0~
C.)
2
0-
4- C.
2.
0 lb1 15 20 25 30
FRACTION NUMBER
FIG. 8. Velocity sedimentation of infected cells
treated with rifampin at different times during infec-
tion. JAl cells were grown to 5 x 108 cellslml, and
MVL51 was added to a multiplicity ofinfection about
10. After 5 min at 37 C, the cells were spun down and
resuspended in prewarmed tryptose broth. At 0 and
90 min after resuspension, 15-ml aliquots were re-
moved and 100 pg ofrifampicin per ml was added for
30 min. During the last 10 min at each time point,
cells were labeled with 40 ,Ci of13H]deoxythymidine
per ml. Labeling was terminated by adding an equal
volume of ice-cold Tris-EDTA-NaCl-NaCN buffer.
The infected cells were washed, mixed with 32p_
labeled marker MVL51 DNA lysed by 0.4% Sar-
kosyl, and sedimented in 5 to 20% high-salt sucrose
gradients for 16 h at 24,000 rpm using an SW27
rotor. The direction of sedimentation is from left to
right. (a) Treated from 0 to 30 min with rifampin; (b)
treated from 90 to 120 min with rifampin. Symbols:(A) untreated and (0) treated infected cells. (c) Part
ofthe rifampin-treated sample in (b) was centrifuged
at 12,000 rpm for 5 min at 4 C, washed, and resus-
pended in prewarmed tryptose broth. Forty minutes
after resuspension, cell lysate was prepared and cen-
trifuged as described above. The RFI and RFII posi-
tions, relative to the marker, were calculated as in the
legend to Fig. 7.
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the cells' RNA polymerase, making it rifampin
sensitive. Finally, the viral transcription com-
plex might be different from that of the cell,
since it has been shown that RNA polymerase
can bind at the promotor site in two configura-
tions, one sensitive and one resistant to rifam-
pin (1).
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